A Randomised, Double-blind, Double-dummy, Parallel-group Multicenter Study to Demonstrate Improvement in Symptoms of Constipation and Non-inferiority in Analgesic Efficacy in Subjects With Non-malignant or Malignant Pain That Require Around-the-clock Opioid Therapy Taking 50/25 - 80/40 mg Twice Daily as Oxycodone/Naloxone Prolonged Release (OXN PR) Tablets Compared to Subjects Taking 50 - 80 mg Twice Daily Oxycodone Prolonged Release (OxyPR) Tablets Alone
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Oxycodone/naloxone (Primary) ; Oxycodone
- Indications Cancer pain; Constipation; Pain
- Focus Registrational; Therapeutic Use
- Acronyms TEMPiT
- Sponsors Mundipharma GmbH
- 14 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 29 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov
- 29 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov